Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · Clinitech Laboratory Limited · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Clinitech Laboratory Limited BSE: 544220
Healthcare › Healthcare › Healthcare Services › Healthcare Service Provider
Clinitech Laboratory Limited
StateQ4 FY26 filed
Last close · 7 Oct 2026₹32.00
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA— · — · —
Clinitech Laboratory Limited is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
₹ crore · consolidated
FY26
Revenue
9
EBITDA (ex other income)
—
margin %
—
Owners' profit
—
EPS, as reported (₹)
1.83
ROE % · ROCE %
— · 6.6
Debt / equity (x)
—
Cash from operations
(1)
Capex
(1)
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Clinitech Laboratory Limited · 28 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 1 quarters
₹ crore
Q4 FY26
Revenue
4
Profit before tax
0
Net profit
—
EPS (₹)
0.52
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
Company
M.cap ₹ cr
P/E
P/B
EV/EBITDA
ROE %
ROCE %
Rev CAGR 5y %
EBITDA m. %
DR. LAL PATH LABS LTD.
31,676
45.6
12.46
36.8
20.1
24.8
11.8
35.0
VIJAYA DIAGNOSTIC CEN LTD
14,858
79.2
15.52
41.4
18.1
16.8
—
46.4
METROPOLIS HEALTHCARE LTD
11,403
23.6
7.48
27.2
12.5
14.4
10.5
25.8
THYROCARE TECH LTD
7,875
28.9
13.44
28.7
27.8
33.2
10.9
33.9
NEPHROCARE HEALTH SERV L
6,272
64.8
5.62
24.8
6.9
8.6
—
25.3
SURAKSHA DIAGNOSTIC LTD
1,615
45.1
6.63
16.4
12.9
11.5
—
36.0
KRSNAA DIAGNOSTICS LTD
1,609
16.5
1.64
8.3
10.3
8.4
—
27.7
3B BLACKBIO DX LTD.
1,199
20.0
3.61
14.1
18.1
22.5
(8.9)
52.6
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
Metric
Company
Group median
Rank
Better than
P/E (TTM)
61.5
23.6
19 of 25
25%
ROCE
5.9
6.1
16 of 29
46%
Market cap
7
34
27 of 30
10%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Clinitech Laboratory Limited · 28 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
Next day %
5-day %
22 Oct 2026 · RPT regulations not applicable, Clinitech is below SME threshold
compliance
minimal
—
—
6 Oct 2026 · Clinitech Laboratory: Q2 FY27 SEBI Reg 74(5) compliance certificate filed
compliance
minimal
—
—
26 Sept 2026 · Trading window closed from Oct 1 for half-yearly results
compliance
minimal
—
—
24 Aug 2026 · Clinitech Laboratory fixes AGM on Sep 24, 2026 via video conferencing
compliance
minimal
—
—
22 Aug 2026 · Notice of 16th AGM on September 24, 2026 via video conferencing
board shareholder meetings
low
—
—
22 Aug 2026 · Clinitech Lab 16th AGM on Sep 24, 2026; book closure Sep 18 to 24
board shareholder meetings
low
—
—
22 Aug 2026 · Clinitech Lab files FY26 Annual Report; AGM set for Sept 24
results
medium
—
—
17 Aug 2026 · Board approves FY26 report, fixes 16th AGM date and book closure dates
management changes
low
—
—
12 Aug 2026 · Board meeting on Aug 17 to approve AGM notice and Board report
board shareholder meetings
low
—
—
7 Jul 2026 · RTA confirms Reg 74(5) compliance; all shares held in demat form
compliance
minimal
—
—
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
